Pharmacologic inhibition of AMD is achieved with SAM486, and combining this agent with DFMO to inhibit both rate-limiting polyamine synthetic enzymes in TH-MYCN homozygous mice was able to prevent tumor initiation in 40% of mice when used pre-emptively, confirming the requirement for polyamine sufficiency downstream of MYC in tumor initiation [69]. The gene discussed is MYC; the disease is neoplasm.